Ketamine Troches vs. Intramuscular Injection: Key Differences

Is ketamine more effective intramuscular or subcutaneous? The two routes are comparably effective because both skip the digestive tract and avoid the liver's first-pass metabolism, so if you're weighing IM against SC, the honest answer is that effectiveness is similar between them. The real difference is where and how each is used: IM shows up most often in mental health and ketamine clinics, while subcutaneous injection is more common in palliative care and home hospice pain management.

This article focuses on the comparison most patients and providers actually weigh: sublingual ketamine troches versus intramuscular injection. Both offer far higher bioavailability than swallowing ketamine as a capsule, and unlike IV infusion, neither requires the full equipment of a dedicated infusion clinic, though IM injection still needs a clinician or a trained caregiver to administer it. Understanding how troche absorption works explains why the numbers below differ so much between routes.

Intramuscular injection delivers ketamine directly into muscle tissue, where it absorbs into the bloodstream through surrounding capillaries. The deltoid (shoulder) and vastus lateralis (thigh) are the most common injection sites. IM absorption isn't as instantaneous as IV, but it's significantly faster and more complete than sublingual absorption.

According to StatPearls, a clinical reference maintained by the National Center for Biotechnology Information, intramuscular ketamine reaches a bioavailability of approximately 93 percent, nearly as complete as intravenous administration and far higher than oral or sublingual routes (StatPearls: Ketamine). That means a 35 mg IM dose delivers roughly 32.5 mg of ketamine to systemic circulation, with pharmacokinetics that are easier to predict dose to dose than sublingual delivery.

• Onset: 5 to 15 minutes after injection
• Peak effect: 15 to 30 minutes
• Duration: 30 to 60 minutes of significant effects, with return to near-baseline within 90 to 120 minutes

IM sessions are typically shorter and more intense than troche sessions, with a faster climb and faster resolution. For a full breakdown of sublingual timing, see our troche onset, peak, and duration timeline.

The troche's longer duration and more gradual onset can be therapeutically valuable. Many patients and clinicians report that the extended window allows more time for emotional processing and integration than the faster IM experience. IM's near-complete bioavailability means dosing is more precise and predictable, which is why some providers favor it for acute, symptom-driven treatment.

IM administration requires someone to give the injection, at minimum a trained clinician or, in some protocols, a trained family member. That typically places IM ketamine in:

• Ketamine clinics, where many providers offer both IV and IM options; IM tends to cost less and require less equipment than IV
• Psychiatrist or physician offices, where some prescribers administer IM in-office
• Home settings with trained support, in protocols used for palliative care or chronic pain, where caregivers are trained to give injections

IM cannot currently be self-administered without training, which makes it inherently less autonomous than troche therapy.

Troches, by contrast, are designed for home use by the patient without any injection or clinical procedure. That's their primary practical advantage: patient autonomy and no clinic visit for each dose. For guidance on fitting troches into an ongoing treatment plan, see working with your provider.

IM sessions at ketamine clinics typically cost $250 to $500 per session, somewhat less than IV infusions since IM requires less equipment and staff time, but still a meaningful per-session cost. A standard six-session acute course runs $1,500 to $3,000.

A month of troche therapy (4 to 8 troches at typical maintenance dosing) costs approximately $150 to $400, including compounding pharmacy fees, plus separate provider visit costs. That lower per-dose cost is what makes troches substantially more affordable for ongoing maintenance rather than a single acute course. See our full ketamine troche cost breakdown for what drives pricing, and the Healthcare.gov glossary of insurance and out-of-pocket cost terms for definitions that apply when comparing clinic bills.

IM ketamine is well studied, with numerous clinical trials and retrospective analyses showing rapid antidepressant effects comparable to IV administration. Some researchers report that IM produces a somewhat different pharmacokinetic profile than IV, a faster initial peak and shorter duration, which may shape the therapeutic experience even though both routes are effective for treatment-resistant depression.

The evidence base for troches is smaller but growing. Clinical data from outpatient practices, along with a modest number of published studies, support efficacy for treatment-resistant depression and chronic pain in appropriate patients. Because troche bioavailability varies more from patient to patient, a direct milligram-for-milligram comparison to IM is harder to make. For patients who haven't responded to oral antidepressants and want to try ketamine therapy, current practice generally favors starting with IV or IM for acute treatment, then transitioning to troches for maintenance once a response is established. Our guide to ketamine troches for maintenance therapy covers what that transition typically looks like.

For patients with significant needle phobia, troches offer a clear advantage: no injection. IM administration requires a needle into muscle tissue, which is generally more uncomfortable than IV access because of the fluid volume injected, and it can cause localized soreness lasting one to two days. Repeat injections at the same site can also cause tissue irritation, which is why clinical providers rotate injection sites.

The two routes also produce a different character of experience. IM's faster onset and higher bioavailability typically produce a shorter, more intense session that patients often describe as "telescoped," a rapid rise, an intense peak, and a relatively quick resolution. Troches' gentler onset and gradual come-down are often described as more comfortable, with more time to process emotional content. Neither profile is inherently better; patient preference and therapeutic goals should guide the choice.

Sources referenced in this article: StatPearls: Ketamine, a clinical reference on ketamine pharmacology and therapeutic applications from the National Center for Biotechnology Information; PubChem: Ketamine Compound Summary, a chemical database entry with molecular and pharmacokinetic data from the National Library of Medicine; Healthcare.gov: Glossary, a federal marketplace resource explaining insurance terminology and out-of-pocket healthcare costs.